Sun Pharma Advanced Research Company Ltd, the research arm of Sun Pharmaceuticals, Saturday posted a narrowed first quarter lose on account of higher income and slight decline in total expenditure.
The research arm of Sun Pharmaceuticals reported net lose of Rs 16.50 million in the quarter ended Jun 30. 2015 compared with net lose of Rs 97.4 million during the same period a year ago.
Total income rose during the quarter under consideration rose 21.17% to Rs 434.4 million from Rs 358.5 million a year ago, while total expenditure slightly fell to Rs 452.6 million from Rs 469.5 million a year ago.
Earlier today, SPARC, separately, said it has received complete response letter from the US Food and Drug Administration for its new drug application for preservative-free eye drop, Latanoprost.
Friday, share prices of SPARC ended at Rs 408.80, up 1.01% on the Mumbai Stock Exchange.
No comments:
Post a Comment